# Deucravacitinib Rosacea

> **NCT06532136** · PHASE2 · WITHDRAWN · sponsor: **Icahn School of Medicine at Mount Sinai**

## Conditions studied

- Papulopustular Rosacea

## Interventions

- **DRUG:** Deucravacitinib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06532136
- **Lead sponsor:** Icahn School of Medicine at Mount Sinai
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-11
- **Primary completion:** 2026-01
- **Final completion:** 2026-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** This study is being closed due to sponsor withdrawal of funding and support.
- **Last updated:** 2025-01-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06532136

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06532136, "Deucravacitinib Rosacea". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06532136. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*